ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

Report Redefines Cancer Control Research, Sets the Agenda For Newest NCI Division

October 17, 1997

OMB Ploy Would Delay Funding 1,500 NIH Grants From FY 1985 To 1986; Other Cuts Are Considered

January 18, 1985

Congress Okays NIH Reauthorization, Allows NCI $472 Mil. More

June 12, 1992

CCOPs, Research Base Awards Are Listed

November 19, 1993

New Firm Steps Onto Texas Battleground for Control Over Office-Based Oncology

November 22, 1996

In Brief: Baylor Campus to Build Joint Cancer Center

January 17, 2014